Melanoma is one of the most aggressive cutaneous malignancies that has undergone drastic shifts in the last decade to revolutionise its treatment trajectory. Recent clinical trials such as the MSLT-1 and 2 have shown the value of sentinel nodes in staging and having a therapeutic advantage in treatment of nodal metastases for intermediate thickness melanomas, and immediate complete nodal dissection increasing local disease control but does not increase melanoma specific survival respectively. In one year at a Melbourne based institute, all patients undergoing a nodal basin dissection due to metastatic melanoma were evaluated. Factors included the stage of the primary melanoma - breslow thickness, ulceration and if a sentinel lymph node biopsy was performed. Furthermore patients were classified in terms of how the metastatic disease was detected - incidental on surveillance examinations and/or imaging, or detected clinically by the patient or another doctor. Finally, whether the patients had received immunotherapy prior to their diagnosis of metastatic disease requiring nodal basin dissection. These insights provide useful retrospective information in examining the characteristics of melanoma patients undergoing delayed completion nodal basin dissection.